Drugs / mitragynine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07204171 | Sep 2026 → Mar 2027 expected | — | National Institute on Drug Abuse (NIDA) | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07713771 | Jul 2026 → Jul 2028 expected | myofascial pain syndrome | Prince of Songkla University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mitragynine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07204171 ↗ |
| Action | Activate | “Mu opioid receptor partial agonist” NCT07204171 ↗ |
| Route | Oral | “oral administration in fasted state” NCT07204171 ↗ |